Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) SVP Paul Treacy sold 1,309 shares of the business’s stock in a transaction on Friday, August 10th. The shares were sold at an average price of $176.61, for a total transaction of $231,182.49. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of NASDAQ:JAZZ opened at $175.37 on Tuesday. The firm has a market capitalization of $10.64 billion, a P/E ratio of 15.65, a price-to-earnings-growth ratio of 0.96 and a beta of 0.90. Jazz Pharmaceuticals PLC has a 1 year low of $128.58 and a 1 year high of $184.00. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.76 and a quick ratio of 3.62.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $3.49 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.23 by $0.26. The firm had revenue of $500.48 million during the quarter, compared to analysts’ expectations of $469.85 million. Jazz Pharmaceuticals had a net margin of 24.20% and a return on equity of 25.47%. equities analysts anticipate that Jazz Pharmaceuticals PLC will post 11.64 EPS for the current year.

Several research firms have recently commented on JAZZ. Stifel Nicolaus boosted their price target on shares of Jazz Pharmaceuticals from $180.00 to $205.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Cantor Fitzgerald set a $203.00 price target on shares of Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 7th. BidaskClub cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 28th. BMO Capital Markets boosted their price target on shares of Jazz Pharmaceuticals from $201.00 to $206.00 and gave the company an “outperform” rating in a report on Wednesday, August 8th. Finally, Seaport Global Securities restated a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eighteen have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $188.67.

A number of large investors have recently modified their holdings of JAZZ. BlackRock Inc. lifted its position in Jazz Pharmaceuticals by 64.0% during the 2nd quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock worth $753,311,000 after acquiring an additional 1,706,417 shares during the last quarter. FMR LLC lifted its position in Jazz Pharmaceuticals by 12.1% during the 2nd quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock worth $1,143,203,000 after acquiring an additional 715,595 shares during the last quarter. Congress Asset Management Co. MA acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $87,276,000. AGF Investments Inc. acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $78,345,000. Finally, Fiera Capital Corp acquired a new position in Jazz Pharmaceuticals during the 2nd quarter worth $54,662,000. Hedge funds and other institutional investors own 90.44% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Understanding Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.